Tianchen Bio-B (01779) announced interim results. Shareholders' losses of 135 million yuan increased by 43.1% year-on-year

Zhitongcaijing · 3d ago

According to the Zhitong Finance App, Tianchen Bio-B (01779) announced interim results for the six months ended June 30, 2026. The group obtained additional revenue and revenue of RMB 3.401 million (same unit), an increase of 3809.2% over the previous year; the owner of the parent company should have accounted for a loss of 135 million yuan, an increase of 43.1% over the previous year; and a loss of 2.18 yuan per share.

The Group's R&D costs increased by about 60.8% from 67.3 million yuan for the six months ended June 30, 2025 to 108 million yuan for the six months ended June 30, 2026, mainly due to an increase of 26 million yuan in clinical trial costs, mainly due to the promotion of LP-003 phase II clinical trials for CRSWnP and phase III clinical trials for CSU, and the start of clinical development of LP-005 related indications; and the cost of raw materials and consumables increased by 10.2 million yuan due to LP-003 and LP-005 CDMO This is due to the increase in raw materials required for the event.